Glutaminase Inhibitor Discovery and Nanoparticle-Enhanced Delivery for Cancer Therapy

Case ID:
C13142
Glutaminase Inhibitor Discovery and Nanoparticle-Enhanced Delivery for cancer therapy

JHU REF: C13142

 

Invention novelty: An improved glutaminase (GLS) inhibitors delivery system to enhance efficacy and prolong glutaminase inhibitor drug levels in tumor for improve treatment of pancreatic cancer.

 

Value Proposition: Currently available glutaminase inhibitors are generally poorly soluble, metabolically unstable, and/or require high doses, which together reduce their efficacy and therapeutic index. Johns Hopkins researchers have developed more potent inhibitors and tumor-penetrating stealth nanoparticles to more effectively deliver the new potent glutaminase inhibitors. This new delivery system offers the following advantages:

•       Inhibitors can be administered safely.

•       Provide dramatically improved tumor drug exposure.

•       Results in greater efficacy.

 

Technical Details: Johns Hopkins researchers used the structural information about the binding of BPTES to glutaminase to synthesize modification of BPTES to develop inhibitors with substantially improved potency. Taking advantage of the lipophilic nature the molecule was encapsulated into nanoparticles for sustained drug delivery.

 

Looking for Partners: To develope and commercialize the glutaminase inhibitors and the nanoparticle formulation for cancer therapy.

 

Stage of Development: Discovery, Preclinical

 

Data Availability: Under CDA/NDA

 

Patent Status: Pending

 

Publication(s)/Associated Cases:  WO 2016/007647



Categories: Therapeutic/drug delivery vehicle



Keywords: Glutaminase inhibitor, Nanoparticle-enhanced delivery, Pancreatic ductal adenocarcinoma, cancer therapy
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
GLUTAMINASE INHIBITOR DISCOVERY AND NANOPARTICLE-ENHANCED DELIVERY FOR CANCER THERAPY PCT: Patent Cooperation Treaty United States 15/324,835 10,660,861 7/8/2015 5/26/2020 11/1/2035 Granted
GLUTAMINASE INHIBITOR DISCOVERY AND NANOPARTICLE-ENHANCED DELIVERY FOR CANCER THERAPY DIV: Divisional United States 16/853,276 11,191,732 4/20/2020 12/7/2021 7/8/2035 Granted
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Nakisha Holder
nickki@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum